Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. (AARD): 3 pipeline candidates · 2 upcoming catalysts · ~14 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
14.4 months
D/E 0.13 · 0% dilution
Lead: Phase 3
3 candidates
2 upcoming, next in ~287d
N/A
A transparent, data-derived signal for Aardvark Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$86.2M
Cash
$62.4M
Quarterly Burn
$18.9M
Runway
14.4 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| ARD-101 | Phase 3 |
| ARD-101 (denatonium acetate monohydrate) | Phase 3 |
| ARD-201 | Phase 3 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
79
Total value held
$26.3M
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 1,295,677 | $4.9M |
| vanguard capital management llc | 1,108,202 | $4.2M |
| laurion capital management lp | 1,034,459 | $3.9M |
| blackrock, inc. | 792,571 | $3.0M |
| tetragon partners gp ltd | 316,621 | $1.2M |
| geode capital management, llc | 309,449 | $1.2M |
| adage capital partners gp, l.l.c. | 300,000 | $1.1M |
| state street corp | 199,322 | $751K |
| two sigma investments, lp | 163,355 | $616K |
| ubs group ag | 157,888 | $595K |
Showing top 10 of 79 institutional holders of Aardvark Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Aardvark Therapeutics, Inc.'s pipeline?
Aardvark Therapeutics, Inc. (AARD) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aardvark Therapeutics, Inc.'s lead drug candidate?
Aardvark Therapeutics, Inc.'s most advanced tracked candidate is ARD-101 (Phase 3) for Hyperphagia.
What is Aardvark Therapeutics, Inc.'s next catalyst?
Aardvark Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperp" — expected April 1, 2027.
What is Aardvark Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aardvark Therapeutics, Inc. has approximately 14.4 months of cash runway.
What is Aardvark Therapeutics, Inc.'s market capitalization?
Aardvark Therapeutics, Inc.'s market capitalization is approximately $86.2M.
Get the full picture on Aardvark Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.